- Home
- EPAM vs LEGN Comparison
EPAM vs LEGN Comparison
Compare EPAM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- LEGN
- Stock Information
- Founded
- EPAM 1993
- LEGN 2014
- Country
- EPAM United States
- LEGN United States
- Employees
- EPAM N/A
- LEGN N/A
- Industry
- EPAM EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- LEGN Health Care
- Exchange
- EPAM Nasdaq
- LEGN Nasdaq
- Market Cap
- EPAM 8.9B
- LEGN 6.3B
- IPO Year
- EPAM 2012
- LEGN 2020
- Fundamental
- Price
- EPAM $162.45
- LEGN $32.12
- Analyst Decision
- EPAM Buy
- LEGN Strong Buy
- Analyst Count
- EPAM 15
- LEGN 12
- Target Price
- EPAM $219.67
- LEGN $70.82
- AVG Volume (30 Days)
- EPAM 602.9K
- LEGN 1.5M
- Earning Date
- EPAM 11-06-2025
- LEGN 11-11-2025
- Dividend Yield
- EPAM N/A
- LEGN N/A
- EPS Growth
- EPAM 0.62
- LEGN N/A
- EPS
- EPAM 7.02
- LEGN N/A
- Revenue
- EPAM $5,071,013,000.00
- LEGN $796,838,000.00
- Revenue This Year
- EPAM $16.65
- LEGN $70.27
- Revenue Next Year
- EPAM $7.23
- LEGN $50.28
- P/E Ratio
- EPAM $23.14
- LEGN N/A
- Revenue Growth
- EPAM 9.73
- LEGN 74.75
- 52 Week Low
- EPAM $138.15
- LEGN $27.34
- 52 Week High
- EPAM $269.00
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- EPAM 62.25
- LEGN 44.37
- Support Level
- EPAM $151.60
- LEGN $31.60
- Resistance Level
- EPAM $157.49
- LEGN $33.09
- Average True Range (ATR)
- EPAM 4.92
- LEGN 1.50
- MACD
- EPAM 2.25
- LEGN 0.08
- Stochastic Oscillator
- EPAM 93.15
- LEGN 33.50
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.